shakt1 stable cell lines telomerase  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    ATCC shakt1 stable cell lines telomerase
    (A) Representative confocal images showing immunofluorescence staining of VE-cadherin on HMEC monolayers transfected with either scrambled ShRNA or ShRNA targeting Akt1. (B) Representative Western blot images and band densitometry quantification of stable ShControl and <t>ShAkt1</t> HMEC lysates showing reduced Akt1 expression in ShAkt1 HMEC compared to ShControl HMEC (n=3). (C) Quantification of the gap area in control and Akt1 knockdown HMEC monolayers normalized to the total area (n=4). (D) Quantification of the number of gaps in control and Akt1 knockdown HMEC monolayers normalized to the number of nuclei per field (n=4). (E) Representative confocal images showing VE-cadherin staining on the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment. (F) Quantification of the number of gaps in the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment (n=4). Data are represented as mean ± SD. *P<0.01, #P<0.05, scale bar 20 μm.
    Shakt1 Stable Cell Lines Telomerase, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shakt1 stable cell lines telomerase/product/ATCC
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    shakt1 stable cell lines telomerase - by Bioz Stars, 2024-04
    94/100 stars

    Images

    1) Product Images from "Modulation of long-term endothelial-barrier integrity is conditional to the cross-talk between Akt and Src signaling"

    Article Title: Modulation of long-term endothelial-barrier integrity is conditional to the cross-talk between Akt and Src signaling

    Journal: Journal of cellular physiology

    doi: 10.1002/jcp.25791

    (A) Representative confocal images showing immunofluorescence staining of VE-cadherin on HMEC monolayers transfected with either scrambled ShRNA or ShRNA targeting Akt1. (B) Representative Western blot images and band densitometry quantification of stable ShControl and ShAkt1 HMEC lysates showing reduced Akt1 expression in ShAkt1 HMEC compared to ShControl HMEC (n=3). (C) Quantification of the gap area in control and Akt1 knockdown HMEC monolayers normalized to the total area (n=4). (D) Quantification of the number of gaps in control and Akt1 knockdown HMEC monolayers normalized to the number of nuclei per field (n=4). (E) Representative confocal images showing VE-cadherin staining on the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment. (F) Quantification of the number of gaps in the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment (n=4). Data are represented as mean ± SD. *P<0.01, #P<0.05, scale bar 20 μm.
    Figure Legend Snippet: (A) Representative confocal images showing immunofluorescence staining of VE-cadherin on HMEC monolayers transfected with either scrambled ShRNA or ShRNA targeting Akt1. (B) Representative Western blot images and band densitometry quantification of stable ShControl and ShAkt1 HMEC lysates showing reduced Akt1 expression in ShAkt1 HMEC compared to ShControl HMEC (n=3). (C) Quantification of the gap area in control and Akt1 knockdown HMEC monolayers normalized to the total area (n=4). (D) Quantification of the number of gaps in control and Akt1 knockdown HMEC monolayers normalized to the number of nuclei per field (n=4). (E) Representative confocal images showing VE-cadherin staining on the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment. (F) Quantification of the number of gaps in the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment (n=4). Data are represented as mean ± SD. *P<0.01, #P<0.05, scale bar 20 μm.

    Techniques Used: Immunofluorescence, Staining, Transfection, shRNA, Western Blot, Expressing

    (A–B) Representative Western blot images and corresponding bar graph of Akt Ser473 phosphorylation and total-Akt in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (C–D) Representative Western blot images and corresponding bar graph of Src Tyr416 phosphorylation and total-Src in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (E–F) Real-time changes and a bar graph showing the quantification of changes in the ShControl and ShAkt1 HMEC-barrier resistance upon treatment with either vehicle (PBS) or 5 ng/ml TGFβ1 as measured using ECIS equipment. Data are represented as mean ± SD. (n=3), *p<0.01.
    Figure Legend Snippet: (A–B) Representative Western blot images and corresponding bar graph of Akt Ser473 phosphorylation and total-Akt in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (C–D) Representative Western blot images and corresponding bar graph of Src Tyr416 phosphorylation and total-Src in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (E–F) Real-time changes and a bar graph showing the quantification of changes in the ShControl and ShAkt1 HMEC-barrier resistance upon treatment with either vehicle (PBS) or 5 ng/ml TGFβ1 as measured using ECIS equipment. Data are represented as mean ± SD. (n=3), *p<0.01.

    Techniques Used: Western Blot

    shakt1 stable cell lines telomerase  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    ATCC shakt1 stable cell lines telomerase
    (A) Representative confocal images showing immunofluorescence staining of VE-cadherin on HMEC monolayers transfected with either scrambled ShRNA or ShRNA targeting Akt1. (B) Representative Western blot images and band densitometry quantification of stable ShControl and <t>ShAkt1</t> HMEC lysates showing reduced Akt1 expression in ShAkt1 HMEC compared to ShControl HMEC (n=3). (C) Quantification of the gap area in control and Akt1 knockdown HMEC monolayers normalized to the total area (n=4). (D) Quantification of the number of gaps in control and Akt1 knockdown HMEC monolayers normalized to the number of nuclei per field (n=4). (E) Representative confocal images showing VE-cadherin staining on the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment. (F) Quantification of the number of gaps in the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment (n=4). Data are represented as mean ± SD. *P<0.01, #P<0.05, scale bar 20 μm.
    Shakt1 Stable Cell Lines Telomerase, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shakt1 stable cell lines telomerase/product/ATCC
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    shakt1 stable cell lines telomerase - by Bioz Stars, 2024-04
    94/100 stars

    Images

    1) Product Images from "Modulation of long-term endothelial-barrier integrity is conditional to the cross-talk between Akt and Src signaling"

    Article Title: Modulation of long-term endothelial-barrier integrity is conditional to the cross-talk between Akt and Src signaling

    Journal: Journal of cellular physiology

    doi: 10.1002/jcp.25791

    (A) Representative confocal images showing immunofluorescence staining of VE-cadherin on HMEC monolayers transfected with either scrambled ShRNA or ShRNA targeting Akt1. (B) Representative Western blot images and band densitometry quantification of stable ShControl and ShAkt1 HMEC lysates showing reduced Akt1 expression in ShAkt1 HMEC compared to ShControl HMEC (n=3). (C) Quantification of the gap area in control and Akt1 knockdown HMEC monolayers normalized to the total area (n=4). (D) Quantification of the number of gaps in control and Akt1 knockdown HMEC monolayers normalized to the number of nuclei per field (n=4). (E) Representative confocal images showing VE-cadherin staining on the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment. (F) Quantification of the number of gaps in the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment (n=4). Data are represented as mean ± SD. *P<0.01, #P<0.05, scale bar 20 μm.
    Figure Legend Snippet: (A) Representative confocal images showing immunofluorescence staining of VE-cadherin on HMEC monolayers transfected with either scrambled ShRNA or ShRNA targeting Akt1. (B) Representative Western blot images and band densitometry quantification of stable ShControl and ShAkt1 HMEC lysates showing reduced Akt1 expression in ShAkt1 HMEC compared to ShControl HMEC (n=3). (C) Quantification of the gap area in control and Akt1 knockdown HMEC monolayers normalized to the total area (n=4). (D) Quantification of the number of gaps in control and Akt1 knockdown HMEC monolayers normalized to the number of nuclei per field (n=4). (E) Representative confocal images showing VE-cadherin staining on the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment. (F) Quantification of the number of gaps in the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment (n=4). Data are represented as mean ± SD. *P<0.01, #P<0.05, scale bar 20 μm.

    Techniques Used: Immunofluorescence, Staining, Transfection, shRNA, Western Blot, Expressing

    (A–B) Representative Western blot images and corresponding bar graph of Akt Ser473 phosphorylation and total-Akt in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (C–D) Representative Western blot images and corresponding bar graph of Src Tyr416 phosphorylation and total-Src in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (E–F) Real-time changes and a bar graph showing the quantification of changes in the ShControl and ShAkt1 HMEC-barrier resistance upon treatment with either vehicle (PBS) or 5 ng/ml TGFβ1 as measured using ECIS equipment. Data are represented as mean ± SD. (n=3), *p<0.01.
    Figure Legend Snippet: (A–B) Representative Western blot images and corresponding bar graph of Akt Ser473 phosphorylation and total-Akt in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (C–D) Representative Western blot images and corresponding bar graph of Src Tyr416 phosphorylation and total-Src in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (E–F) Real-time changes and a bar graph showing the quantification of changes in the ShControl and ShAkt1 HMEC-barrier resistance upon treatment with either vehicle (PBS) or 5 ng/ml TGFβ1 as measured using ECIS equipment. Data are represented as mean ± SD. (n=3), *p<0.01.

    Techniques Used: Western Blot

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    ATCC shakt1 stable cell lines telomerase
    (A) Representative confocal images showing immunofluorescence staining of VE-cadherin on HMEC monolayers transfected with either scrambled ShRNA or ShRNA targeting Akt1. (B) Representative Western blot images and band densitometry quantification of stable ShControl and <t>ShAkt1</t> HMEC lysates showing reduced Akt1 expression in ShAkt1 HMEC compared to ShControl HMEC (n=3). (C) Quantification of the gap area in control and Akt1 knockdown HMEC monolayers normalized to the total area (n=4). (D) Quantification of the number of gaps in control and Akt1 knockdown HMEC monolayers normalized to the number of nuclei per field (n=4). (E) Representative confocal images showing VE-cadherin staining on the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment. (F) Quantification of the number of gaps in the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment (n=4). Data are represented as mean ± SD. *P<0.01, #P<0.05, scale bar 20 μm.
    Shakt1 Stable Cell Lines Telomerase, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shakt1 stable cell lines telomerase/product/ATCC
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    shakt1 stable cell lines telomerase - by Bioz Stars, 2024-04
    94/100 stars
      Buy from Supplier

    Image Search Results


    (A) Representative confocal images showing immunofluorescence staining of VE-cadherin on HMEC monolayers transfected with either scrambled ShRNA or ShRNA targeting Akt1. (B) Representative Western blot images and band densitometry quantification of stable ShControl and ShAkt1 HMEC lysates showing reduced Akt1 expression in ShAkt1 HMEC compared to ShControl HMEC (n=3). (C) Quantification of the gap area in control and Akt1 knockdown HMEC monolayers normalized to the total area (n=4). (D) Quantification of the number of gaps in control and Akt1 knockdown HMEC monolayers normalized to the number of nuclei per field (n=4). (E) Representative confocal images showing VE-cadherin staining on the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment. (F) Quantification of the number of gaps in the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment (n=4). Data are represented as mean ± SD. *P<0.01, #P<0.05, scale bar 20 μm.

    Journal: Journal of cellular physiology

    Article Title: Modulation of long-term endothelial-barrier integrity is conditional to the cross-talk between Akt and Src signaling

    doi: 10.1002/jcp.25791

    Figure Lengend Snippet: (A) Representative confocal images showing immunofluorescence staining of VE-cadherin on HMEC monolayers transfected with either scrambled ShRNA or ShRNA targeting Akt1. (B) Representative Western blot images and band densitometry quantification of stable ShControl and ShAkt1 HMEC lysates showing reduced Akt1 expression in ShAkt1 HMEC compared to ShControl HMEC (n=3). (C) Quantification of the gap area in control and Akt1 knockdown HMEC monolayers normalized to the total area (n=4). (D) Quantification of the number of gaps in control and Akt1 knockdown HMEC monolayers normalized to the number of nuclei per field (n=4). (E) Representative confocal images showing VE-cadherin staining on the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment. (F) Quantification of the number of gaps in the vehicle (DMSO), Src inhibitor (PP2) and Akt inhibitor (TCBN) treated HMEC monolayers 24 hours after treatment (n=4). Data are represented as mean ± SD. *P<0.01, #P<0.05, scale bar 20 μm.

    Article Snippet: Cell culture and preparation of ShAkt1 stable cell lines Telomerase-immortalized HMECs (CRL-4025; ATCC, Manassas, VA) were maintained in EBM-2 with a Growth factor-2 Bullet Kit (Lonza; Walkersville, MD).

    Techniques: Immunofluorescence, Staining, Transfection, shRNA, Western Blot, Expressing

    (A–B) Representative Western blot images and corresponding bar graph of Akt Ser473 phosphorylation and total-Akt in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (C–D) Representative Western blot images and corresponding bar graph of Src Tyr416 phosphorylation and total-Src in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (E–F) Real-time changes and a bar graph showing the quantification of changes in the ShControl and ShAkt1 HMEC-barrier resistance upon treatment with either vehicle (PBS) or 5 ng/ml TGFβ1 as measured using ECIS equipment. Data are represented as mean ± SD. (n=3), *p<0.01.

    Journal: Journal of cellular physiology

    Article Title: Modulation of long-term endothelial-barrier integrity is conditional to the cross-talk between Akt and Src signaling

    doi: 10.1002/jcp.25791

    Figure Lengend Snippet: (A–B) Representative Western blot images and corresponding bar graph of Akt Ser473 phosphorylation and total-Akt in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (C–D) Representative Western blot images and corresponding bar graph of Src Tyr416 phosphorylation and total-Src in HMEC lysates treated in the presence and absence of 5 ng/ml TGFβ1 for 1–24 hours, respectively. (E–F) Real-time changes and a bar graph showing the quantification of changes in the ShControl and ShAkt1 HMEC-barrier resistance upon treatment with either vehicle (PBS) or 5 ng/ml TGFβ1 as measured using ECIS equipment. Data are represented as mean ± SD. (n=3), *p<0.01.

    Article Snippet: Cell culture and preparation of ShAkt1 stable cell lines Telomerase-immortalized HMECs (CRL-4025; ATCC, Manassas, VA) were maintained in EBM-2 with a Growth factor-2 Bullet Kit (Lonza; Walkersville, MD).

    Techniques: Western Blot